Connect directly with a patient representative in your area; just fill out the info below:

By submitting this form, I give permission for a Strongbridge representative to contact me by phone, email, or text message. Your information will not be used for marketing communication or other purposes. Please review the Strongbridge Biopharma® Terms of Use and Privacy Statement for further information.

Here is the contact information of your dedicated support.

Disease Management

Primary Periodic Paralysis attacks can be reduced

How is Primary Periodic Paralysis diagnosed?

Getting a confirmed diagnosis for Primary Periodic Paralysis can take some time because the symptoms can be confused with other more common conditions, such as psychiatric conditions or cardiovascular disorders.1-3

There are several factors doctors will consider when determining if you have Primary Periodic Paralysis:

  • Your personal experience with attacks of paralysis: Understanding various details about your attacks is important. This includes what parts of your body are typically affected, what tends to trigger the attacks (eg, types of food or certain activity), and the age you first started getting attacks.2,4,5
  • People in your family who have the condition: Recognizing a family history can speed up diagnosis because Primary Periodic Paralysis is generally inherited.1
  • Various laboratory and medical tests: Performing certain tests can help rule out other diseases. Tests in people with symptoms of Primary Periodic Paralysis often include blood testing, muscle function testing, and genetic testing to determine if you have an abnormality in 1 of the genes associated with the condition.4,5

How is Primary Periodic Paralysis treated?

Aside from lifestyle changes, there are 2 main approaches to managing your Primary Periodic Paralysis attacks. The first is treatment for an attack that is already underway. The second works to help manage the occurrence of attacks.

Treatment during an attack4,5
  • For hyperkalemic periodic paralysis: Getting mild exercise and eating high-carbohydrate foods can help4
  • For hypokalemic periodic paralysis: Taking oral potassium can lessen the severity of an attack and make it not last as long5
  • In case of a severe attack: Some attacks can be so severe that you may need medical attention, so you should talk to your doctor about the best plan for managing severe attacks5

Patient Ambassador

“I have had a few bouts of profound muscle weakness when exposed to very cold wind, but I have not had an attack of temporary paralysis affecting my full body in [two] years.”

Medical and nonmedical approaches help attacks4,5
  • Treatment with KEVEYIS: KEVEYIS is the only approved prescription treatment for Primary Periodic Paralysis—ask your doctor if KEVEYIS is an appropriate option for you
  • Avoid your triggers: Know your particular triggers and work with your doctor on a plan to avoid them

Patient Ambassador

“I have noticed that, with KEVEYIS, I have fewer attacks and they are not as long in duration. While I do need to pace myself and follow a very strict diet, I find that I am able to manage my symptoms.”

KEVEYIS is helping patients with Primary Periodic Paralysis gain greater control over the disease by decreasing attacks.6,7 Learn more.

Patient Ambassador

“I also prepare to prevent potential episodes. I am mindful of triggers, like cold weather. I try not to get stressed, and I take deep breaths, making sure I take time for art and hanging out with my dog. I prepare for what I need daily, like making sure I’m hydrated and paying attention to what the weather’s going to be like.”


Indication and Important Safety Information

What is KEVEYIS?

KEVEYIS (pronounced keh-VAY-iss) (dichlorphenamide) is a prescription drug used to treat primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and other similar diseases.

What should you tell your healthcare provider before taking KEVEYIS?

Tell your doctor if you are allergic to dichlorphenamide or other sulfa drugs; if you take high doses of aspirin, or if you have lung or liver disease; if you are pregnant, plan to become pregnant, or are breastfeeding or plan to breastfeed.

What should you know about KEVEYIS?

  • Severe allergic and other reactions have happened with sulfonamides (drugs such as KEVEYIS) and have sometimes been fatal. Stop taking KEVEYIS at the first sign of skin rash, swelling, difficulty breathing, or any other unexpected side effect or reaction, and call 911 right away.
  • Tell your healthcare provider if you take aspirin or if another healthcare provider instructs you to begin taking aspirin. High doses of aspirin should not be taken with KEVEYIS.
  • KEVEYIS can cause your body to lose potassium, which can lead to heart problems. Your healthcare provider will measure the potassium levels in your blood before you start treatment and at certain times during treatment.
  • Tell your healthcare provider about all other prescription and over-the-counter medicines you take, including supplements, as some medicines can interact with KEVEYIS.
  • While taking KEVEYIS, your body may produce too much acid or may not be able to remove acid from the body. Your healthcare provider may run tests on a regular basis to check for signs of acid buildup.
  • KEVEYIS may increase your risk of falling. Tell your healthcare provider right away if you experience a fall while taking KEVEYIS.
  • The risks of falls and acid buildup are greater in elderly patients.
  • It is not known whether KEVEYIS is safe or effective for people younger than 18 years of age.

What are the most common side effects with KEVEYIS?

The most common side effects are a feeling of numbness, tingling or burning (“pins and needles”) in the toes, feet, hands or fingers; trouble with memory or thinking; feeling confused; and unpleasant taste in the mouth.

These are not all of the possible side effects of KEVEYIS. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.


  1. Charles G, Zheng C, Lehmann-Horn F, Jurkat-Rott K, Levitt J. Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals. J Neurol. 2013;260:2606-2613.
  2. Cavel-Greant D, Lehmann-Horn F, Jurkat-Rott K. The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients. Acta Myol. 2012;31:126-133.
  3. Arya SN. Periodic paralysis. Journal, Indian Academy of Clinical Medicine. 2002;3:374-382.
  4. Weber F, Jurkat-Rott K, Lehmann-Horn F. Hyperkalemic Periodic Paralysis. NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. 2016.
  5. Vicart S, Sternberg D, Arzel-Hezode M, et al. Hypokalemic Periodic Paralysis. NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. 2014.
  6. KEVEYIS Prescribing Information. Feasterville-Trevose, PA: Strongbridge Biopharma; 2019.
  7. Sansone VA, Burge J, McDermott MP, et al; for the Muscle Study Group. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology. 2016;86:1408-1416.